Halozyme Therapeutics Company Profile (NASDAQ:HALO)

About Halozyme Therapeutics

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: HALO
  • CUSIP: 40637H10
Key Metrics:
  • Previous Close: $12.04
  • 50 Day Moving Average: $12.09
  • 200 Day Moving Average: $11.19
  • 52-Week Range: $7.52 - $14.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.63
  • P/E Growth: -0.25
  • Market Cap: $1.57B
  • Outstanding Shares: 128,154,000
  • Beta: 2.27
Profitability:
  • Net Margins: -44.60%
  • Return on Equity: -405.28%
  • Return on Assets: -26.67%
Debt:
  • Debt-to-Equity Ratio: -16.66%
  • Current Ratio: 5.18%
  • Quick Ratio: 4.93%
Additional Links:
Companies Related to Halozyme Therapeutics:

Analyst Ratings

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $13.96 (13.76% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetDetails
1/23/2017Piper Jaffray CompaniesReiterated RatingBuy$20.00View Rating Details
1/6/2017Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
11/8/2016Jefferies Group LLCReiterated RatingSell$6.75View Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$12.00View Rating Details
9/8/2016Wells Fargo & CoReiterated RatingBuyView Rating Details
6/6/2016Canaccord GenuityReiterated RatingBuy$11.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00View Rating Details
2/24/2016Barclays PLCLower Price TargetOverweight$27.00 -> $16.00View Rating Details
6/22/2015J P Morgan Chase & CoBoost Price TargetOverweight$20.00 -> $25.00View Rating Details
6/1/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details
4/20/2015BMO Capital MarketsSet Price TargetBuy$26.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.28)$37.94 millionN/AView Earnings Details
11/7/2016Q316($0.27)($0.23)$34.43 million$31.90 millionViewListenView Earnings Details
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.14)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-0.90 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.20)($0.17)($0.19)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.24)($0.24)($0.24)
Q4 20161($0.24)($0.24)($0.24)
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.26)($0.26)($0.26)
Q4 20171($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)
Insider Ownership Percentage: 16.60%
Institutional Ownership Percentage: 82.94%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
DateHeadline
News IconHalozyme Therapeutics, Inc. (NASDAQ:HALO) Future Growth Projections From Analysts - Rockville Register (NASDAQ:HALO)
rockvilleregister.com - February 24 at 11:57 PM
News IconWhat Does The Chart For Halozyme Therapeutics, Inc. (HALO) Tell Us Presently? - NY Stock News (NASDAQ:HALO)
nystocknews.com - February 24 at 11:57 PM
schaeffersresearch.com logoWall Street Gets Ready For GDP Data, Yellen Speech (NASDAQ:HALO)
www.schaeffersresearch.com - February 23 at 5:35 PM
finance.yahoo.com logoHalozyme Therapeutics To Present At Upcoming Healthcare Conferences (NASDAQ:HALO)
finance.yahoo.com - February 23 at 5:35 PM
News IconAnalysts Peer Into Their Crystal Balls For Halozyme Therapeutics, Inc. (NASDAQ:HALO): Where Is It headed? - Winfield Review (NASDAQ:HALO)
winfieldreview.com - February 22 at 10:48 PM
News IconStock Tracker: Earnings & Estimates for Halozyme Therapeutics, Inc ... - Aiken Advocate (NASDAQ:HALO)
aikenadvocate.com - February 22 at 10:48 PM
News IconFollowing the Numbers on Shares of Halozyme Therapeutics, Inc ... - Benton Bulletin (NASDAQ:HALO)
bentonbulletin.com - February 17 at 8:42 AM
News IconHalozyme Therapeutics Inc HALO Financial and Strategic SWOT Analysis Review [Updated: 19012017] Prices from USD $125 (NASDAQ:HALO)
www.bioportfolio.com - February 16 at 5:32 PM
4-traders.com logoMabVax Therapeutics : Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 (NASDAQ:HALO)
www.4-traders.com - February 13 at 11:37 AM
News IconCompany Focus: Zooming in on Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Baldwin Journal (NASDAQ:HALO)
baldwinjournal.com - February 10 at 11:19 PM
News IconNews Impact Score Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) At 92 - Stock Observer (NASDAQ:HALO)
www.thestockobserver.com - February 10 at 11:19 PM
News IconForward Earnings Estimate of Halozyme Therapeutics, Inc.(HALO) - Highland Mirror (NASDAQ:HALO)
www.highlandmirror.com - February 10 at 11:19 PM
reuters.com logoBRIEF-First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing (NASDAQ:HALO)
www.reuters.com - February 6 at 5:38 PM
News IconHalozyme Therapeutics, Inc. (NASDAQ:HALO) Quarterly EPS Projection At $-0.3 - Stock Observer (NASDAQ:HALO)
www.thestockobserver.com - February 5 at 10:25 PM
News IconAustralian PM, Trump offer mixed messages on refugee deal (NASDAQ:HALO)
mundoaguaysaneamiento.net - February 2 at 11:16 PM
fool.com logoWhy Halozyme Therapeutics, Inc. Jumped 15.6% in January - Motley Fool (NASDAQ:HALO)
www.fool.com - February 2 at 6:14 PM
fool.com logoWhy Halozyme Therapeutics, Inc. Jumped 15.6% in January (NASDAQ:HALO)
www.fool.com - February 2 at 9:31 AM
News IconEarnings Forecast Research on Halozyme Therapeutics, Inc. (HALO) - Morning Outlook (NASDAQ:HALO)
www.morningoutlook.com - February 2 at 4:23 AM
News IconIridian Asset Management LLC Trimmed Its Sealed Air Corp (SEE) Holding as Valuation Declined (NASDAQ:HALO)
randolphguide.com - February 1 at 6:19 PM
finance.yahoo.com logoHalozyme To Host Fourth Quarter 2016 Financial Results Conference Call (NASDAQ:HALO)
finance.yahoo.com - February 1 at 6:19 PM
News IconInvestor Guide: Check on Technical Levels for Halozyme Therapeutics Inc. (HALO) - Springdale Times (NASDAQ:HALO)
springdaletimes.com - January 31 at 4:19 AM
capitalcube.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 27, 2017 (NASDAQ:HALO)
www.capitalcube.com - January 27 at 7:31 PM
News IconHalozyme Therapeutics Inc HALO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:HALO)
www.bioportfolio.com - January 27 at 12:12 AM
News IconEarnings in Full Force, Analysts Take Aim at Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Wall Street Beacon (NASDAQ:HALO)
wsbeacon.com - January 26 at 7:09 PM
News IconNews Impact Score Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Set At 77 - Stock Observer (NASDAQ:HALO)
www.thestockobserver.com - January 20 at 6:55 PM
News IconWill The Needle Move For Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:HALO)
wsbeacon.com - January 19 at 7:22 PM
News IconThe Analysts Set Halozyme Therapeutics Inc. (HALO) Price Target at $15.54 (NASDAQ:HALO)
flapship.com - January 18 at 6:02 PM
capitalcube.com logoETFs with exposure to Halozyme Therapeutics, Inc. : January 17, 2017 (NASDAQ:HALO)
www.capitalcube.com - January 17 at 3:37 PM
istreetwire.com logoEye Catching Stocks: Halozyme Therapeutics, Inc. (HALO), State Street Corporation (STT), Express Scripts Holding ... - iStreetWire (NASDAQ:HALO)
istreetwire.com - January 17 at 9:59 AM
News IconEPS Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) At $-0.3 - Stock Observer (NASDAQ:HALO)
www.thestockobserver.com - January 16 at 9:16 AM
capitalcube.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 16, 2017 (NASDAQ:HALO)
www.capitalcube.com - January 16 at 9:16 AM
News IconThe Brokerages gives Consensus Recommendation of "Buy" to Halozyme Therapeutics Inc. (HALO) (NASDAQ:HALO)
instantcrickets.com - January 13 at 11:47 PM
News IconFlorida Man Used Device to Cover License Plate at Tolls: FHP (NASDAQ:HALO)
hypelee.com - January 13 at 6:47 PM
News IconTeachers Advisors LLC Sells 890 Shares of Halozyme Therapeutics, Inc. (HALO) (NASDAQ:HALO)
onemma.net - January 13 at 6:47 PM
prnewswire.com logoHalozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare - PR Newswire (press release) (NASDAQ:HALO)
www.prnewswire.com - January 11 at 6:13 PM
finance.yahoo.com logoWhy trader is selling Halozyme calls (NASDAQ:HALO)
finance.yahoo.com - January 11 at 6:13 PM
investopedia.com logoHalozyme Estimates 2017 Revenue of $115M to $130M (NASDAQ:HALO)
www.investopedia.com - January 11 at 6:13 PM
streetinsider.com logoHalozyme Therapeutics (HALO) Sees FY17 Rev. of $115M-$130M - StreetInsider.com (NASDAQ:HALO)
www.streetinsider.com - January 11 at 4:34 AM
nasdaq.com logoHalozyme Therapeutics Reaches Analyst Target Price (NASDAQ:HALO)
www.nasdaq.com - January 10 at 6:32 PM
biz.yahoo.com logoHALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:HALO)
biz.yahoo.com - January 10 at 6:32 PM
fool.com logoHere's Why Halozyme Therapeutics Fell as Much as 11.1% Today (NASDAQ:HALO)
www.fool.com - January 10 at 6:32 PM
smarteranalyst.com logoCompany Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Provides Clinical Program Updates and 2017 Financial Guidance (NASDAQ:HALO)
www.smarteranalyst.com - January 10 at 4:22 AM
reuters.com logoBRIEF-Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln (NASDAQ:HALO)
www.reuters.com - January 9 at 6:20 PM
finance.yahoo.com logoCan the Rally in Halozyme (HALO) Shares Continue? (NASDAQ:HALO)
finance.yahoo.com - January 9 at 6:20 PM
finance.yahoo.com logoHalozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference (NASDAQ:HALO)
finance.yahoo.com - January 9 at 6:20 PM
finance.yahoo.com logo4:08 pm Halozyme Therapeutics guides 2017 revenue below expectations (NASDAQ:HALO)
finance.yahoo.com - January 9 at 6:20 PM
biz.yahoo.com logoHALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure (NASDAQ:HALO)
biz.yahoo.com - January 9 at 6:20 PM
News IconHalozyme Therapeutics, Inc. (NASDAQ:HALO) Broker Price Targets For The Coming Week (NASDAQ:HALO)
vgtoday.net - January 9 at 3:26 AM
News IconMarket Scope: Taking a Look at Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Wall Street Beacon (NASDAQ:HALO)
wsbeacon.com - January 8 at 10:26 PM
fool.com logoWhy Halozyme Therapeutics, Inc Fell 40.6% in 2016 - Motley Fool (NASDAQ:HALO)
www.fool.com - January 8 at 10:26 PM

Social

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?

7 analysts have issued 1-year target prices for Halozyme Therapeutics' shares. Their predictions range from $6.75 to $20.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $13.96 in the next twelve months.

When will Halozyme Therapeutics announce their earnings?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Halozyme Therapeutics stock?

Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Third Security LLC (15.06%), Iridian Asset Management LLC CT (8.38%), FMR LLC (5.28%), State Street Corp (2.98%), Senzar Asset Management LLC (0.96%) and Franklin Resources Inc. (0.81%). Company insiders that own Halozyme Therapeutics stock include Kenneth J Kelley and Laurie Stelzer.

Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, Allianz Asset Management AG, Brown Advisory Inc., Renaissance Technologies LLC, Guggenheim Capital LLC, J. Goldman & Co LP and Putnam Investments LLC.

Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Third Security LLC, Iridian Asset Management LLC CT, Senzar Asset Management LLC, State Street Corp, Oxford Asset Management, A.R.T. Advisors LLC, Russell Investments Group Ltd. and Pacad Investment Ltd..

How do I buy Halozyme Therapeutics stock?

Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Halozyme Therapeutics stock cost?

One share of Halozyme Therapeutics stock can currently be purchased for approximately $12.27.

Halozyme Therapeutics (NASDAQ:HALO) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Earnings History Chart

Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Dividend History Chart

Dividend Payments by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Last Updated on 2/25/2017 by MarketBeat.com Staff